Exact Sciences Corp at Canaccord Genuity Growth Conference (Virtual) Transcript
Hi. Welcome to the 40th Annual Canaccord Genuity Global Growth Conference. I'm Max Masucci, lead diagnostics analyst at Canaccord. And I'm pleased to be joined by Exact Sciences, one of the fastest-growing companies in my coverage universe over the past 5 years. And one of the biggest success stories in noninvasive screening for early-stage cancer due to its Cologuard test for colorectal cancer. So despite growing its Cologuard business from under $2 million in revenues in 2014 to over $810 million in 2020, Exact remains just 6% penetrated in its Cologuard opportunity with a stated goal of achieving 40% penetration over time. Beyond Cologuard, Exact has a Precision Oncology segment which it acquired in 2018 through its acquisition of Genomic Health. Exact is a market-leading R&D engine, which we expect to drive shareholder returns equally as spectacularly as what we have seen over the past 5 years. So I'm really pleased to welcome back Exact Sciences CFO, Jeff Elliott; and Megan Jones, Investor Relations. Thanks again for joining us
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
